Clinical evaluation of the polymerase chain reaction for the rapid diagnosis of tuberculosis

V C C Cheng, W C Yam, I F N Hung, P C Y Woo, S K P Lau, B S F Tang, K Y Yuen

Aims: Use of the polymerase chain reaction for the detection of Mycobacterium tuberculosis (TB PCR) as a basis for making clinical decisions on the initiation of antituberculosis treatment was studied.

Methods: A retrospective study involving a cohort of 155 patients being investigated for tuberculosis in an infectious disease consultation service was undertaken. TB PCR was performed on pulmonary and extrapulmonary specimens from these patients. The sensitivity of TB PCR was analysed.

Results: Of the 155 patients, 144 fitted the clinical diagnosis of tuberculosis, and 112 of them were culture positive for M tuberculosis. Sixty (58.3%) patients with clinical features suggestive of tuberculosis received antituberculosis treatment based on positive TB PCR alone. Of 224 clinical specimens (138 pulmonary and 86 extrapulmonary) sent for TB PCR, 148 (99 pulmonary and 49 extrapulmonary) were positive in 117 patients. Of the 690 clinical specimens sent for culture, 279 were positive for M tuberculosis in 112 patients. The diagnostic sensitivity of TB PCR was 75.9% (85 of 112) and 81.3% (117 of 144) in patients with culture confirmed and clinically diagnosed tuberculosis, respectively. Using culture as the gold standard, the overall sensitivity of TB PCR was 78.3%, and for pulmonary and extrapulmonary specimens it was 82.3% and 72.0%, respectively.

Conclusions: TB PCR is a rapid and reliable test in the diagnosis and management of tuberculosis.

Microbiological investigation for M tuberculosis

We performed investigations for M tuberculosis, including AFB smear examination and culture, on relevant clinical specimens of all patients with suspected tuberculosis. TB PCR was performed once a week on pulmonary and extrapulmonary specimens in the following clinical settings: (1) patients with typical radiological changes compatible with pulmonary tuberculosis; (2) patients with radiological changes of old tuberculosis but presenting with new pulmonary infiltrates; (3) patients with community acquired pneumonia not responding to appropriate antibiotic treatment; and (4) patients undergoing invasive procedures, such as image guided or surgical drainage and biopsy for sterile sites in the investigation of extrapulmonary tuberculosis. Histological examination for M tuberculosis was also performed if clinically indicated.

Microbiological processing of clinical specimens

All specimens were collected in γ irradiated disposable plastic containers. A direct smear was prepared for the auramine fluorescent stain and, if positive, the Ziehl-Neelsen stain was performed for confirmation. The respiratory specimens were decontaminated and digested by treatment with an equal volume of sputolysin/sodium hydroxide (4%) for 30 minutes at room temperature with rocking. After neutralisation with 20 ml of 0.067M sodium phosphate buffer (pH 5.3), the mixture was centrifuged at 2750 ×g for 30 minutes. After discarding the supernatant, 400–500 µl of the sediment was irradiated disposable plastic containers. A direct smear was prepared for the auramine fluorescent stain and, if positive, the Ziehl-Neelsen stain was performed for confirmation. The respiratory specimens were decontaminated and digested by treatment with an equal volume of sputolysin/sodium hydroxide (4%) for 30 minutes at room temperature with rocking. After neutralisation with 20 ml of 0.067M sodium phosphate buffer (pH 5.3), the mixture was centrifuged at 2750 ×g for 30 minutes. After discarding the supernatant, 400–500 µl of the sediment was obtained. For early morning urine, 20 ml samples were centrifuged at 2750 ×g for 30 minutes. The sediments were digested with 2% sodium hydroxide, followed by neutralisation with 0.067M phosphate buffer (pH 5.3). After centrifugation, sediments were obtained. For the other
non-respiratory samples, such as sterile body fluid or tissue aspirates, specimens were microcentrifuged at 12,000 × g for 10 minutes to collect the sediments. For sediments of both respiratory and non-respiratory specimens, about 60 µL of the sediment was inoculated into two Löwenstein-Jensen medium culture bottles and incubated at 37°C for up to eight weeks. Solid medium slants were considered positive when visible colonies grew. The colonies were further confirmed as mycobacteria by the Ziehl-Neelsen stain. Cultures positive for AFB were identified by the AccuProbe hybridisation assay (Gen-Probe, San Diego, California, USA), according to the manufacturer’s instructions. For mycobacteria other than M. tuberculosis, conventional biochemical tests were performed for identification.

The rest of the sediment was transferred to an Eppendorf tube and stored at −20°C if not immediately processed.

**Manual one tube nested PCR for the IS6110 gene sequence for the detection of *M. tuberculosis***

For the digested sediments, the Roche Cobas Amplicor (Roche Diagnostics, Berlin, Germany) extraction protocol was used, as described previously. A volume of 500 µL wash solution was mixed with the sediment. After centrifugation at 15,000 × g for 10 minutes the supernatant was decanted, 100 µL of lysis reagent was added, and the mixture was vortexed, followed by incubation at 60°C for 45 minutes. Extraction was terminated by adding 100 µL of neutralisation reagent. Each PCR reaction contained 10 µL of the DNA extract. The two sets of primers used for amplification were derived from the gene sequence encoding the insertion sequence IS6110 as follows: external primers were derived from position 367 to 392 (5′-CTCGACACAGCTGTACATTTAAGGGTTC-3′) and position 769 to 746 (5′-TGTGGCCGGATCAGCGATCGTGGT-3′); and internal primers were derived from position 455 to 472 (5′-CTGCACACAGGTCAACGG-3′) and position 670 to 652 (5′-CTGTTCGCCGTTGATCTCTG-3′). The reaction mixture consisted of 10 mM Tris/HC1 (pH 8.3), 50 mM KCl, 2 mM MgCl2, 0.15 mM dATP, dGTP, dCTP, and 0.45 mM dUTP, 2 pmol external primers, 75 pmol internal primers, 2 U AmpliTaq Gold polymerase (Perkin Elmer, Foster City, California, USA), and 0.5 U heat labile uracil-N-glycosylase (Roche Diagnostics) in a total reaction volume of 100 µL. The mixture was first incubated at 37°C for 10 minutes in order to destroy any contaminating amplicons, and then at 94°C for 12 minutes to activate the AmpliTaq polymerase, followed by subsequent temperature cycling at 94°C for 45 seconds and 72°C for 1.5 minutes for the first 15 cycles, followed by 94°C for 45 seconds, 55°C for 45 seconds, and 72°C for one minute for 45 cycles. Positive and negative controls were included in each run and all precautions to prevent cross contamination were observed. Amplified products were electrophoresed through a 2% agarose gel in Tris borate buffer. Target bands of 21 bp were visualised by staining with ethidium bromide.

**Diagnosis and treatment of *M. tuberculosis***

Preliminary diagnosis of *M. tuberculosis* was based on a positive AFB smear, TB PCR, or tissue histology results during the initial investigation. A definitive diagnosis of tuberculosis was made by positive culture results. For those patients with negative culture for *M. tuberculosis*, a clinical diagnosis was made by an investigators’ consensus with respect to the clinical and radiological presentation and progression, tuberculin skin tests, haematological findings, pathological findings (when available), and clinical response to antituberculosis treatment.

Antituberculosis treatment was given to patients with a preliminary or definitive diagnosis of tuberculosis, or empirically if clinical suspicion of *M. tuberculosis* was high.

**Microbiological investigation for *M. tuberculosis***

In total, 437 pulmonary specimens (sputum, bronchial aspirates, bronchoalveolar lavage, and gastric aspirates) and 253 extrapulmonary (cerebrospinal fluid, pleural effusion, peritoneal fluid, joint fluid, bone marrow aspiration, bone biopsy, tissue biopsy, lymph nodes, urine, and stools) specimens were obtained for AFB smear and culture examinations in 155 patients. Eighty eight smears were positive in 35 patients and 279 cultures were positive for *M. tuberculosis* in 112 patients, respectively. The diagnostic sensitivity of the AFB smear was 31.3% (35 of 112) and 24.3% (35 of 144) in culture confirmed and clinically diagnosed tuberculosis, respectively. The yield from AFB culture was 77.8% when clinical diagnosis was used as reference.

In total, 224 clinical specimens were requested from 155 patients for TB PCR (138 pulmonary specimens and 86 extrapulmonary specimens), in which 148 specimens (99 pulmonary specimens and 49 extrapulmonary specimens) were positive in 117 patients. Figure 2 shows the correlations between TB PCR and AFB smear and culture results. One sample in one patient with a positive AFB smear who was culture positive for *M. tuberculosis* showed negative results in the TB PCR test. A PCR inhibitor was detected in the sample extract from this patient. Eight patients with histological features of tuberculosis but who were negative in TB PCR had positive *M. tuberculosis* cultures. Thirty-four patients with a positive smear and TB PCR had a positive culture for *M. tuberculosis*. Another 32 patients had a positive smear and a positive TB PCR in the initial investigation, but culture was subsequently positive in 51 patients. Those patients with a positive TB PCR but a negative culture had clinical and radiological results that were suggestive of active tuberculosis. TB PCR was positive in 85 of 112 patients who were culture positive for *M. tuberculosis*. The diagnostic sensitivity of TB PCR was 75.9% (85 of 112) and 81.3% (117 of 144) in culture confirmed and clinically diagnosed tuberculosis, respectively. TB PCR was positive in 101 of the 129 specimens (79 pulmonary specimens and 50 extrapulmonary specimens) where cultures were positive. The overall sensitivity of the assay was 78.3%, and that of pulmonary and extrapulmonary specimens was 82.3% and 72.0%, respectively (Table 1). In the 11 patients in whom an alternative diagnosis other than tuberculosis was made, 54 and 11 clinical specimens were negative for mycobacterial culture and TB PCR, respectively, resulting 100% specificity of TP PCR. Tissue specimens were available in 20 patients for histological examination and 12 of them had evidence of mycobacterial infection.

**Diagnosis and treatment of *M. tuberculosis***

In the initial investigation, 121 patients had laboratory evidence of *M. tuberculosis* infection, which included AFB
smear and TB PCR positive in 34, AFB smear positive but TB PCR negative in one, AFB smear negative but TB PCR positive in 78, and histological features of mycobacterial infection in eight patients. Standard antituberculosis treatment including isoniazid, rifampicin, pyrazinamide, and ethambutol was given to 103 patients when the initial work up results became available. Thirty four (33%) of 103 patients were treated because of positive smear and TB PCR results, and 60 (58.3%) patients received antituberculosis therapy based on positive TB PCR results. Treatment was started because of a positive AFB smear result in one and a positive histological result alone in eight patients. Antituberculosis treatment was not

Figure 1  Decision for initiating antituberculosis treatment (anti-TB Rx) in 155 patients based on clinical and laboratory findings. TB PCR, polymerase chain reaction for Mycobacterium tuberculosis.

Figure 2  The correlation between polymerase chain reaction for Mycobacterium tuberculosis (TB PCR) and conventional work up for M tuberculosis in 155 patients. * Those patients with positive TB PCR but negative culture results had clinical and radiological results that were suggestive of active tuberculosis.
given in 18 patients because of severe comorbidity in 15, an advanced age of 102 in one, and the patient’s refusal for fear of potential side effects of treatment in two, despite positive TB PCR results at the initial investigation for TB. In 34 patients with negative AFB smears, empirical antituberculosis treatment was given as above while waiting for the TB PCR results in 10 (6.9%) patients. There was pulmonary or miliary tuberculosis in six patients, tuberculous meningitis in three, and tuberculous spondylitis and peritonitis in one. Five of these 10 patients turned out to have a positive TB PCR within five days of starting treatment. The remaining 24 patients with negative results in both the AFB smear and TB PCR were investigated further and an alternative diagnosis was made in 11 patients. Fourteen patients received antituberculosis treatment when the culture results were available, including two patients who refused initial treatment. Therefore, 127 (82%) of 155 patients received antituberculosis treatment in this cohort, of whom 118 completed the course of treatment. Nine patients defaulted follow up after the initiation of treatment.

**DISCUSSION**

The decision to initiate antituberculosis treatment based on the pretreatment nucleic acid amplification assay on both respiratory and non-respiratory specimens was studied. In our series, of 144 patients with a clinical diagnosis of *M. tuberculosis* infection, only 25% had positive results on AFB smear examination, but about 80% had a positive TB PCR assay result. Almost 60% patients received antituberculosis treatment based on positive TB PCR as the sole result in the initial investigation, and more than 70% of them had subsequent culture confirmation of *M. tuberculosis*. Without this rapid assay, delay in giving the appropriate treatment would probably have occurred.

Although the Food and Drug Administration of the USA recommended that PCR should only be performed for rapid diagnosis in respiratory specimens of either AFB smear positive or negative samples, nucleic acid amplification has been studied extensively in patients with extrapulmonary tuberculosis using either in house or commercial kits. The sensitivity ranged between 42% and 93% in culture positive specimens. In our centre uses a manual in house, single tube, nested PCR using IS6110 as a target site for the rapid diagnosis of pulmonary and extrapulmonary tuberculosis, with a specificity of 99.7%. The manual assay also showed comparable results to the commercial kits when respiratory specimens were evaluated. In our study, the overall sensitivity of the TB PCR assay was 78.3%, and 72% for extrapulmonary specimens, which is similar to that seen in another centre using IS6110 as a target site for laboratory diagnosis. However, the result for pleural fluid in our study was particularly poor, with a sensitivity of only 33.3%, in contrast to another study, which found the sensitivity of PCR to be 81% for pleural fluid. The presence of inhibitors could not explain the discrepancy in these results. Interestingly, we found a positive TB PCR in an endocervical swab, which has not been reported in the literature.

"Of 144 patients with a clinical diagnosis of *Mycobacterium tuberculosis* infection, only 25% had positive results on acid fast bacilli smear examination, but about 80% had a positive *Mycobacterium tuberculosis* polymerase chain reaction result".

Although TB PCR appears to be a rapid, sensitive, and specific diagnostic assay, the results should be interpreted with care in the clinical setting. In our study, 32 patients had a positive TB PCR but a negative culture subsequently. In such cases, there is a clinical dilemma of whether antituberculosis treatment should be maintained or discontinued. As long as precautions have been taken to avoid cross contamination, the positive TB PCR may indicate the presence of non-viable AFB, particularly in patients with a history of tuberculosis in the past. However, a negative AFB culture cannot preclude a clinical diagnosis of tuberculosis, particularly in patients with clinical and radiological features suggestive of active tuberculosis, as demonstrated in our patients. There can be a variety of reasons for a positive TB PCR but negative AFB culture. For example, the *M. tuberculosis* count may be low at the tissue level or the organisms may not be viable as a result of the decontamination procedure used when handling respiratory specimens. Therefore, TB PCR can be used to complement culture in selected patients.

| Table 1 Evaluation of TB PCR in culture confirmed *Mycobacterium tuberculosis* |
|----------------------------------|-----------------|-----------------|-----------------|-----------------|
|                                  | Total number of  | Number of TB    | Number of TB    | Sensitivity of TB PCR |
|                                  | culture positive | PCR positive    | PCR negative    | PCR              |
| Pulmonary specimens              | 79               | 65              | 14              | 82.3%            |
| Sputum                           | 39               | 31              | 8               | 79.5%            |
| Bronchoalveolar lavage           | 40               | 34              | 6               | 85%              |
| Extrapulmonary specimens         | 50               | 36              | 14              | 72%              |
| Tissue                           | 16               | 13              | 3               | 81.2%            |
| Aspirates                        | 13               | 9               | 4               | 69.2%            |
| Cerebrospinal fluid              | 10               | 8               | 2               | 80%              |
| Pleural fluid                    | 6                | 2               | 4               | 33.3%            |
| Early morning urine              | 4                | 3               | 1               | 75%              |
| Endocervical swab                | 1                | 1               | 0               | 100%             |
| Total                            | 129              | 101             | 28              | 78.3%            |

**Take home messages**

- The polymerase chain reaction for *Mycobacterium tuberculosis* (TB PCR) is a rapid and reliable method for the diagnosis of both pulmonary and extrapulmonary tuberculosis, with an overall sensitivity of 78.3% and a specificity of 100%
- It enabled antituberculosis treatment to be started early in more than half of the patients studied
- Because of the relatively low sensitivity of TB PCR, clinical judgment remains the ultimate decision in the management of tuberculosis
Recent advances in the molecular diagnosis of tuberculosis involving the detection of bacterial mRNA encoding the ubiquitous 85B antigen in viable *M. tuberculosis* by reverse transcriptase PCR and reverse transcriptase strand displacement amplification assay may overcome the above difficulty. Because the mRNA is more rapidly destroyed in the cells than rRNA or genomic DNA, having a half life of only a few minutes, it can differentiate between viable and non-viable *M. tuberculosis*. Thus, it may become useful for the diagnosis of active tuberculosis and provide a tool to monitor the therapeutic efficacy.

In conclusion, TB PCR is a rapid and reliable method in the diagnosis of tuberculosis, which allowed early initiation of antituberculosis treatment in more than 50% of the studied patients in our cohort. However, because of the relatively low sensitivity of TB PCR, clinical judgment remains the ultimate decision in the management of tuberculosis.

Authors’ affiliations

V C C Cheng, W C Yam, F N Hung, P C Y Woo, S K P Lou, B S F Tang, K Y Yuen, Division of Infectious Diseases, Centre of Infection, The University of Hong Kong, University Pathology Building, Queen Mary Hospital, Hong Kong

REFERENCE


www.jclinpath.com
Clinical evaluation of the polymerase chain reaction for the rapid diagnosis of tuberculosis

V C C Cheng, W C Yam, I F N Hung, P C Y Woo, S K P Lau, B S F Tang and K Y Yuen

doi: 10.1136/jcp.2003.012658

Updated information and services can be found at:
http://jcp.bmj.com/content/57/3/281

These include:

**References**
This article cites 19 articles, 9 of which you can access for free at:
http://jcp.bmj.com/content/57/3/281#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- **Clinical diagnostic tests** (805)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/